Shopping Cart
Remove All
Your shopping cart is currently empty
SAR247799 (S1P1 agonist 3) is a selective and G-protein-biased S1P1 agonist that activates downstream G-protein signaling pathways more preferentially than β-blocker proteins and internalized signaling pathways, activates S1P 1 on endothelial cells without causing receptor desensitization, and protects the endothelium without affecting lymphocyte populations, and can be used to study type 2 diabetes, endothelial dysfunction and vascular hyperpermeability.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $1,199 | 7-10 days | 7-10 days |
| Description | SAR247799 (S1P1 agonist 3) is a selective and G-protein-biased S1P1 agonist that activates downstream G-protein signaling pathways more preferentially than β-blocker proteins and internalized signaling pathways, activates S1P 1 on endothelial cells without causing receptor desensitization, and protects the endothelium without affecting lymphocyte populations, and can be used to study type 2 diabetes, endothelial dysfunction and vascular hyperpermeability. |
| Targets&IC50 | Gi-mediated cAMP (S1P1, HEK293 cells):1.4 nM (EC50), β-arrestin recruitment (S1P1, HEK293 cells):15 nM (EC50) |
| In vitro | SAR247799 is a potent G protein–biased agonist of human S1P1 receptors in HEK293 cells. It showed an EC₅₀ of 1.4 nM in Gi-mediated cAMP inhibition assays, but a much weaker EC₅₀ of 15 nM for β-arrestin recruitment, indicating strong bias toward G protein signaling. In endothelial cells, SAR247799 (1–100 nM) upregulated eNOS and KLF2, promoting vascular protection[1]. |
| In vivo | In Zucker fa/fa rats (a type 2 diabetes model), oral administration of SAR247799 (0.002–0.24 mg/kg daily for 5 weeks) significantly improved arterial compliance, reduced urinary albumin excretion, and increased renal blood flow at low doses (0.007 mg/kg) without causing peripheral lymphopenia. The treatment also increased expression of endothelial genes (eNOS, KLF2), supporting its vascular-protective action via G protein–biased S1P1 activation[1]. |
| Synonyms | SAR 247799, S1P1 agonist 3 |
| Molecular Weight | 425.82 |
| Formula | C21H16ClN3O5 |
| Cas No. | 1315311-14-8 |
| Smiles | O=C(O)COC=1C(=CC(=CC1C)C2=NC3=CN=C(N=C3O2)OC=4C=CC=C(Cl)C4)C |
| Relative Density. | 1.412 g/cm3 (Predicted) |
| Storage | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (46.97 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.7 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.